44,400 Tyra Biosciences (TYRA) stock options granted to director Dable

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tyra Biosciences director Habib J. Dable received a grant of stock options covering 44,400 shares of common stock at an exercise price of $35.12 per share. The options expire on April 15, 2036 and vest monthly in 36 equal installments starting after April 16, 2026, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dable Habib J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	44,400	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 44,400 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 44,400 options Exercise price: $35.12 per share Expiration date: April 15, 2036 +2 more

5 metrics

Stock options granted 44,400 options Grant to director Habib J. Dable on April 16, 2026

Exercise price $35.12 per share Strike price for the 44,400 stock options

Expiration date April 15, 2036 Final exercise date for the granted options

Vesting schedule 1/36 monthly Monthly vesting of options following April 16, 2026, over 36 months

Underlying shares 44,400 shares Common shares underlying the granted stock options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "35.1200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-15T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/36th of the total number of shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/20/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dable Habib J

(Last)

(First)

(Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD

CALIFORNIA

92008

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$35.12	04/16/2026		A		44,400		⁽¹⁾	04/15/2036	Common	44,400	$0	44,400	D

Explanation of Responses:

1. 1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tyra Biosciences (TYRA) report for Habib J. Dable?

Tyra Biosciences reported that director Habib J. Dable received a grant of stock options for 44,400 shares of common stock at an exercise price of $35.12 per share. This is a compensation-related award rather than an open-market stock purchase or sale.

How many Tyra Biosciences (TYRA) shares are covered by the new stock options?

The new stock option grant to Habib J. Dable covers 44,400 shares of Tyra Biosciences common stock. Each option allows the purchase of one share at the fixed exercise price, subject to the vesting schedule and continued service conditions described in the filing footnote.

What is the exercise price and expiration date of Habib J. Dable’s Tyra Biosciences options?

The options granted to Habib J. Dable have an exercise price of $35.12 per share and expire on April 15, 2036. This means he can choose to buy shares at $35.12 any time after vesting and before the expiration date, subject to plan terms.

How do the Tyra Biosciences (TYRA) options granted to Habib J. Dable vest?

The options vest over time, with 1/36th of the 44,400 underlying shares vesting monthly following April 16, 2026, the grant date. Vesting is conditioned on Habib J. Dable’s continuous service to Tyra Biosciences through each monthly vesting date, as disclosed in the footnote.

Is Habib J. Dable’s Tyra Biosciences Form 4 transaction a market buy or sell?

The Form 4 transaction is an acquisition of stock options as a grant, not a market buy or sell of existing shares. It is coded as a grant or award, reflecting compensation in the form of options, with no open-market purchase or sale reported in this filing.

What does the Form 4 tell investors about Habib J. Dable’s holdings in Tyra Biosciences (TYRA)?

After the reported grant, Habib J. Dable holds 44,400 stock options directly, according to the filing. These options relate to 44,400 underlying common shares and will vest over 36 months starting after April 16, 2026, assuming his ongoing service to the company.